Who makes [14C]-BGB-11417?

[14C]-BGB-11417 is developed by BeiGene.

Last reviewed 2026-04-19 · How we verify

[14C]-BGB-11417

BeiGene · Phase 1 active Small molecule

At a glance

Generic name	[14C]-BGB-11417
Also known as	Sonrotoclax
Sponsor	BeiGene
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-BGB-11417 CI brief — competitive landscape report
[14C]-BGB-11417 updates RSS · CI watch RSS
BeiGene portfolio CI